WuXi Biologics (Cayman) Inc.

SEHK:2269 Stock Report

Market Cap: HK$71.3b

WuXi Biologics (Cayman) Management

Management criteria checks 2/4

WuXi Biologics (Cayman)'s CEO is Chris Chen, appointed in Jan 2016, has a tenure of 8.92 years. total yearly compensation is CN¥96.91M, comprised of 4.1% salary and 95.9% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth HK$246.61M. The average tenure of the management team and the board of directors is 2.7 years and 6.9 years respectively.

Key information

Chris Chen

Chief executive officer

CN¥96.9m

Total compensation

CEO salary percentage4.1%
CEO tenure8.9yrs
CEO ownership0.3%
Management average tenure2.7yrs
Board average tenure6.9yrs

Recent management updates

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Recent updates

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Dec 17
Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

Sep 26
After Leaping 29% WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Are Not Flying Under The Radar

WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Sep 12
WuXi Biologics (Cayman) (HKG:2269) Has A Pretty Healthy Balance Sheet

Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With WuXi Biologics (Cayman) Inc.'s (HKG:2269) CEO Compensation And Here's Why

Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Jun 11
Some Confidence Is Lacking In WuXi Biologics (Cayman) Inc. (HKG:2269) As Shares Slide 25%

Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Jun 11
Some WuXi Biologics (Cayman) Inc. (HKG:2269) Shareholders Look For Exit As Shares Take 25% Pounding

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15
Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04
Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

CEO Compensation Analysis

How has Chris Chen's remuneration changed compared to WuXi Biologics (Cayman)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

CN¥3b

Mar 31 2024n/an/a

CN¥3b

Dec 31 2023CN¥97mCN¥4m

CN¥3b

Sep 30 2023n/an/a

CN¥4b

Jun 30 2023n/an/a

CN¥4b

Mar 31 2023n/an/a

CN¥4b

Dec 31 2022CN¥79mCN¥3m

CN¥4b

Sep 30 2022n/an/a

CN¥4b

Jun 30 2022n/an/a

CN¥4b

Mar 31 2022n/an/a

CN¥4b

Dec 31 2021CN¥51mCN¥3m

CN¥3b

Sep 30 2021n/an/a

CN¥3b

Jun 30 2021n/an/a

CN¥3b

Mar 31 2021n/an/a

CN¥2b

Dec 31 2020CN¥31mCN¥3m

CN¥2b

Sep 30 2020n/an/a

CN¥1b

Jun 30 2020n/an/a

CN¥1b

Mar 31 2020n/an/a

CN¥1b

Dec 31 2019CN¥25mCN¥3m

CN¥1b

Sep 30 2019n/an/a

CN¥922m

Jun 30 2019n/an/a

CN¥831m

Mar 31 2019n/an/a

CN¥731m

Dec 31 2018CN¥20mCN¥2m

CN¥631m

Sep 30 2018n/an/a

CN¥520m

Jun 30 2018n/an/a

CN¥410m

Mar 31 2018n/an/a

CN¥331m

Dec 31 2017CN¥24mCN¥2m

CN¥253m

Compensation vs Market: Chris's total compensation ($USD13.28M) is above average for companies of similar size in the Hong Kong market ($USD788.91K).

Compensation vs Earnings: Chris's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Chris Chen (51 yo)

8.9yrs

Tenure

CN¥96,911,000

Compensation

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

Leadership Team

NamePositionTenureCompensationOwnership
Ge Li
Founder & Chairman10.8yrsno datano data
Zhisheng Chen
CEO & Executive Director8.9yrsCN¥96.91m0.35%
HK$ 246.6m
Weichang Zhou
Honorary President of Global Biologics Development9.7yrsCN¥32.89m0.011%
HK$ 8.0m
Ming Tu
CFO & Executive VP3.1yrsno datano data
Lihua Yu
COO & Senior VPless than a yearno datano data
Sherry Gu
Chief Technology Officer and Executive VP of Global Biologics Development Departmentless than a yearno datano data
Jijie Gu
Chief Scientific Officer & President of Global Biologics Researchno datano datano data
Lina Fan
Senior VP & Head of Investor Relationsless than a yearno datano data
He Wang
Chief Compliance Officer2.3yrsno datano data
Li Xiong
VP & Head of Global Human Resourcesno datano datano data
Angus Scott Turner
Senior VP and Head of Global BD & Alliance Managementno datano datano data
Keqiang Shen
Chief Digital Officer4.9yrsno datano data

2.7yrs

Average Tenure

56.5yo

Average Age

Experienced Management: 2269's management team is considered experienced (2.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ge Li
Founder & Chairman10.8yrsno datano data
Zhisheng Chen
CEO & Executive Director10.8yrsCN¥96.91m0.35%
HK$ 246.6m
Weichang Zhou
Honorary President of Global Biologics Development8.6yrsCN¥32.89m0.011%
HK$ 8.0m
Jackson Tai
Independent Non-Executive Director1.6yrsCN¥710.00k0.00063%
HK$ 449.4k
James Larrick
Member of Scientific Advisory Board6.9yrsno datano data
David D. Ho
Member of Scientific Advisory Board6.9yrsno datano data
Wei-Shou Hu
Member of Scientific Advisory Board6.9yrsno datano data
Ram Sasisekharan
Member of Scientific Advisory Board6.9yrsno datano data
William Robert Keller
Independent Non-Executive Director7.6yrsCN¥906.00k0.00053%
HK$ 378.1k
Yanling Cao
Non-Executive Director8.6yrsno datano data
Rolf G. Werner
Member of Scientific Advisory Board1.9yrsno datano data
Kenneth Walton Hitchner
Independent Non-Executive Director4.5yrsCN¥933.00k0.0050%
HK$ 3.5m

6.9yrs

Average Tenure

60yo

Average Age

Experienced Board: 2269's board of directors are considered experienced (6.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 09:04
End of Day Share Price 2024/12/24 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

WuXi Biologics (Cayman) Inc. is covered by 54 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Linda LuBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Bo LiBofA Global Research